Cortexyme to Present at Annual Biomarkers for Alzheimer’s Disease Summit
August 18 2021 - 7:00AM
Business Wire
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal
trial in Alzheimer’s disease with top-line data expected by
mid-November 2021 and a growing pipeline of therapeutics for
degenerative diseases, will participate as a featured speaker
covering its pivotal Phase 2/3 GAIN Trial of atuzaginstat and the
upstream role that P. gingivalis plays in key pathologies of
Alzheimer’s disease at the upcoming Annual Biomarkers for
Alzheimer’s Disease Summit taking place virtually August 24-26,
2021. Cortexyme will present new data demonstrating further
evidence of P. gingivalis infection of the central nervous system
in Alzheimer’s disease as demonstrated by analysis of anti-P.
gingivalis antibodies in cerebrospinal fluid from the GAIN
trial.
Annual Biomarkers for Alzheimer’s Disease Summit
Details
Topic: Use of Novel Biomarkers of P. Gingivalis Infection &
Neuroinflammation in the GAIN Trial: An Ongoing Phase 2/3 Clinical
Trial Assessing the Activity of Atuzaginstat in Patients with Mild
to Moderate Alzheimer’s Disease
- Speaker: Leslie Holsinger, Ph.D., Cortexyme’s Executive Vice
President, Research and Development
- Day/Time: Wednesday, August 25, 2021, at 2:10 p.m. ET followed
by a live Q&A at 3:40 p.m. ET
About Cortexyme
Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage
biopharmaceutical company pioneering upstream therapeutic
approaches designed to improve the lives of patients diagnosed with
Alzheimer’s and other degenerative diseases. The company is
advancing its disease-modifying pivotal GAIN Trial in mild to
moderate Alzheimer's disease with top-line data expected by
mid-November 2021, in addition to growing a proprietary pipeline of
first-in-class small molecule therapeutics for Parkinson’s disease,
periodontitis, and other diseases with high unmet clinical need.
Cortexyme’s lead program targets a specific, infectious pathogen
called P. gingivalis found in the brain and other organs and tied
to degeneration and inflammation in humans and animal models. The
company’s causation evidence for Alzheimer’s disease and the
mechanism of its novel therapeutic has been independently
replicated and confirmed by multiple laboratories around the world,
as well as published in peer-reviewed scientific journals. To learn
more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme
on Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210818005203/en/
Corporate Contact: Stacy Roughan Cortexyme, Inc. Vice
President, Corporate Communications & Investor Relations
ir@cortexyme.com
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Apr 2023 to Apr 2024